Published in Am J Hum Genet on September 21, 2017
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet (2009) 30.09
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics (2010) 13.54
A global reference for human genetic variation. Nature (2015) 12.85
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res (2011) 11.03
Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science (2015) 9.92
Human metabolic individuality in biomedical and pharmaceutical research. Nature (2011) 6.56
Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet (2012) 5.55
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
An atlas of genetic influences on human blood metabolites. Nat Genet (2014) 3.21
Identification of genetic variants that affect histone modifications in human cells. Science (2013) 3.11
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol (2012) 2.39
Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) (2010) 2.23
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem (1998) 2.05
Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat Commun (2014) 1.85
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics (2011) 1.52
WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat Methods (2015) 1.45
DNASU plasmid and PSI:Biology-Materials repositories: resources to accelerate biological research. Nucleic Acids Res (2013) 1.33
Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care (2012) 1.27
Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. PLoS One (2012) 1.27
Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics (2012) 1.07
Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J (2010) 1.02
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood (2012) 0.99
Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS One (2013) 0.98
Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet (2010) 0.97
Acylcarnitines activate proinflammatory signaling pathways. Am J Physiol Endocrinol Metab (2014) 0.96
Acylcarnitines: potential implications for skeletal muscle insulin resistance. FASEB J (2014) 0.94
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology (2004) 0.89
Carnitine Acetyltransferase Mitigates Metabolic Inertia and Muscle Fatigue during Exercise. Cell Metab (2015) 0.88
Global metabolomic profiling targeting childhood obesity in the Hispanic population. Am J Clin Nutr (2015) 0.88
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int (2013) 0.87
Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients. Diabetes Res Clin Pract (1995) 0.85
Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome. Ann Nutr Metab (2012) 0.84
Downregulation of carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion. Diabetes (2014) 0.83
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med (2015) 0.81
Acute hormonal effects on carnitine metabolism in thin and obese subjects: responses to somatostatin, glucagon, and insulin. Metabolism (1981) 0.81
Transorgan fluxes in a porcine model reveal a central role for liver in acylcarnitine metabolism. Am J Physiol Endocrinol Metab (2015) 0.80
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol (2013) 0.80
Long-chain acylcarnitines activate cell stress and myokine release in C2C12 myotubes: calcium-dependent and -independent effects. Am J Physiol Endocrinol Metab (2015) 0.79
Carnitine metabolism in diabetes mellitus. J Pediatr Endocrinol Metab (2002) 0.79
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol (2013) 0.78
Plasma and urine metabolic profiles are reflective of altered beta-oxidation in non-diabetic obese subjects and patients with type 2 diabetes mellitus. Diabetol Metab Syndr (2014) 0.78
The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. Biomed Res Int (2014) 0.77
Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. Eur J Pharmacol (2015) 0.76
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med (2015) 0.75